Prescribing Cystadane

CYSTADANE is available exclusively through the specialty pharmacy Anovo (www.anovorx.com).

For patient home delivery:

  1. Download and fill out a CYSTADANE treatment form.
  2. Fax the form to 1-855-813-2039.
  3. Anovo representatives will work with your office to provide benefit verification and prior authorization support, if needed.
  4. Anovo will ship CYSTADANE to the patient’s home and provide follow-up calls to promote adherence.

For inpatient orders:

  1. Call 1-888-487-4703 and select option 2 to place a wholesale order for inpatient use.
  2. Anovo will work with hospitals to ensure continuity of therapy when transitioning newly diagnosed patients from hospital to home settings.
QUESTIONS? Call Anovo at 1-888-487-4703

Financial Assistance for Patients

Recordati Rare Diseases is committed to reducing financial barriers regarding CYSTADANE.

The following programs are available to assist your patients:

Copay Assistance Program

Assists eligible patients with their insurance copayments or co-insurance for CYSTADANE.

Patient Assistance Program

Helps eligible uninsured or underinsured patients get CYSTADANE.

Anovo will be able to determine whether your patients are eligible for these programs.

INDICATIONS AND USAGE

Cystadane is a methylating agent indicated in pediatric and adult patients for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations. Included within the category of homocystinuria are:

  • Cystathionine beta-synthase (CBS) deficiency
  • 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency
  • Cobalamin cofactor metabolism (cbl) defect

IMPORTANT SAFETY INFORMATION

  • Hypermethioninemia in Patients with CBS Deficiency: CYSTADANE may worsen elevated plasma methionine concentrations and cerebral edema has been reported. Monitor plasma methionine concentrations in patients with CBS deficiency. Keep plasma methionine concentrations below 1,000 micromol/L through dietary modification and, if necessary, a reduction of CYSTADANE dosage.
  • Most common adverse reactions (> 2%) are: nausea and gastrointestinal distress, based on physician survey.
  • To report SUSPECTED ADVERSE REACTIONS, contact Recordati Rare Diseases Inc. at 1-888-575-8344, or FDA at 1‑800-FDA-1088 or www.fda.gov/medwatch.
See More

IMPORTANT SAFETY INFORMATION

  • Hypermethioninemia in Patients with CBS Deficiency: CYSTADANE may worsen elevated plasma methionine concentrations and cerebral edema has been reported. Monitor plasma methionine concentrations in patients with CBS deficiency. Keep plasma methionine concentrations below 1,000 micromol/L through dietary modification and, if necessary, a reduction of CYSTADANE dosage.
  • Most common adverse reactions (> 2%) are: nausea and gastrointestinal distress, based on physician survey.